Archemix: drug discovery innovation based on evolutionary nucleic acid technology platforms
- 1 March 2002
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 7 (5) , S8-S11
- https://doi.org/10.1016/s1359-6446(02)02170-0
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- In vitro selection of nucleoprotein enzymesNature Biotechnology, 2001
- Aptamer Beacons for the Direct Detection of ProteinsAnalytical Biochemistry, 2001
- Immobilized RNA switches for the analysis of complex chemical and biological mixturesNature Biotechnology, 2001
- Rapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technologyNature Biotechnology, 2001
- Mechanism-Based Target Identification and Drug Discovery in Cancer ResearchScience, 2000
- Self-splicing of the Tetrahymena intron from mRNA in mammalian cellsThe EMBO Journal, 1999
- Allosteric selection of ribozymes that respond to the second messengers cGMP and cAMP.Nature Structural & Molecular Biology, 1999
- Design of allosteric hammerhead ribozymes activated by ligand-induced structure stabilizationStructure, 1999
- Engineering precision RNA molecular switchesProceedings of the National Academy of Sciences, 1999
- In vitro selection of an allosteric ribozyme that transduces analytes to ampliconsNature Biotechnology, 1999